Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trialDerek Alderson, Ruth E. Langley, David Cunningham et al.|The Lancet Oncology|2017Cited by 223
Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort studyHannah Sophie Muti, Jakob Nikolas Kather, Jae‐Ho Cheong et al.|The Lancet Digital Health|2021Cited by 120
Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: Results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072).Derek Alderson, David Cunningham, Ruth E. Langley et al.|Journal of Clinical Oncology|2015Cited by 80